{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:52:18Z","timestamp":1794016338660,"version":"4.8.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The key project of basic research from Jinling Hospital, Medical School of Nanjing University","award":["22JCYYZD5"],"award-info":[{"award-number":["22JCYYZD5"]}]},{"name":"The key project from Jiangsu Commission of Health","award":["BK20181239"],"award-info":[{"award-number":["BK20181239"]}]},{"name":"The clinical research project from Jinling Hospital, Medical School of Nanjing University","award":["22LCYY-XH6"],"award-info":[{"award-number":["22LCYY-XH6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03709-x","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T10:53:21Z","timestamp":1740826401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between cancer-associated fibroblasts and prognosis of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: a bioinformatics analysis based on single-cell RNA sequencing"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangzhuang","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingmei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"3","key":"3709_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3709_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.21147\/j.issn.1000-9604.2021.05.01","volume":"33","author":"J Li","year":"2021","unstructured":"Li J, Xu J, Zheng Y, Gao Y, He S, Li H, Zou K, Li N, Tian J, Chen W, et al. Esophageal cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2021;33(5):535\u201347.","journal-title":"Chin J Cancer Res"},{"issue":"4","key":"3709_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393\u2013422.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"3709_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/cac2.12457","volume":"43","author":"M Matz","year":"2023","unstructured":"Matz M, Valkov M, \u0160ekerija M, Luttman S, Caldarella A, Coleman MP, Allemani C. Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000\u20132014 (CONCORD-3). Cancer Commun (London England). 2023;43(9):963\u201380.","journal-title":"Cancer Commun (London England)"},{"key":"3709_CR5","unstructured":"H T, J Y Z HWYF, Y X S JY, Z C Z, D X J, Y Y H MD et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol 2022, 34(2)."},{"key":"3709_CR6","unstructured":"Hong Y, Hui L, Yuping C, Chengchu Z, Wentao F, Zhentao Y, Weimin M, Jiaqing X, Yongtao H, Zhijian C et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg 2021, 156(8)."},{"issue":"5","key":"3709_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3709_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","volume":"23","author":"D Cella","year":"2022","unstructured":"Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, et al. Patient-reported outcomes with first-line nivolumab plus Cabozantinib versus Sunitinib in patients with advanced renal cell carcinoma treated in checkmate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):292\u2013303.","journal-title":"Lancet Oncol"},{"issue":"10302","key":"3709_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"10","key":"3709_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and Progression-Free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916\u201325.","journal-title":"JAMA"},{"issue":"35","key":"3709_CR11","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal Cancer. J Clin Oncol. 2020;38(35):4138\u201348.","journal-title":"J Clin Oncol"},{"key":"3709_CR12","doi-asserted-by":"crossref","unstructured":"Schiffmann LM, Plum PS, Fuchs HF, Babic B, Bruns CJ, Schmidt T. Tumor Microenvironment of Esophageal Cancer. Cancers (Basel) 2021, 13(18).","DOI":"10.3390\/cancers13184678"},{"key":"3709_CR13","doi-asserted-by":"crossref","unstructured":"Klein S, Duda DG. Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. Cancers (Basel) 2021, 13(19).","DOI":"10.3390\/cancers13194919"},{"issue":"5","key":"3709_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ccell.2023.03.001","volume":"41","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu S, Liu T, Zhang S, Lu J, Fan W, Lin L, Xiang T, Yang J, Zhao X, et al. Epithelial cells activate fibroblasts to promote esophageal cancer development. Cancer Cell. 2023;41(5):903\u2013e918908.","journal-title":"Cancer Cell"},{"issue":"11","key":"3709_CR15","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","volume":"12","author":"J Grout","year":"2022","unstructured":"Grout J, Sirven P, Leader A, Maskey S, Hector E, Puisieux I, Steffan F, Cheng E, Tung N, Maurin M, et al. Spatial positioning and matrix programs of Cancer-Associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 2022;12(11):2606\u201325.","journal-title":"Cancer Discov"},{"issue":"11","key":"3709_CR16","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.ccell.2022.09.015","volume":"40","author":"D Foster","year":"2022","unstructured":"Foster D, Januszyk M, Delitto D, Yost K, Griffin M, Guo J, Guardino N, Delitto A, Chinta M, Burcham A, et al. Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell. 2022;40(11):1392\u2013e14061397.","journal-title":"Cancer Cell"},{"issue":"2","key":"3709_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00259-022-05989-1","volume":"50","author":"L Zhao","year":"2023","unstructured":"Zhao L, Pang Y, Chen S, Chen J, Li Y, Yu Y, Huang C, Sun L, Wu H, Chen H, et al. Prognostic value of fibroblast activation protein expressing tumor volume calculated from [ Ga]Ga-FAPI PET\/CT in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imag. 2023;50(2):593\u2013601.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"3709_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13046-023-02697-y","volume":"42","author":"J He","year":"2023","unstructured":"He J, Chen Y, Zeng F, Huang Q, Zhang H, Wang S, Yu S, Pang X, Liu Y, Xu X, et al. Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer. J Experimental Clin cancer Research: CR. 2023;42(1):136.","journal-title":"J Experimental Clin cancer Research: CR"},{"issue":"1","key":"3709_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41467-023-35832-6","volume":"14","author":"C Hanley","year":"2023","unstructured":"Hanley C, Waise S, Ellis M, Lopez M, Pun W, Taylor J, Parker R, Kimbley L, Chee S, Shaw E, et al. Single-cell analysis reveals prognostic fibroblast subpopulations linked to molecular and immunological subtypes of lung cancer. Nat Commun. 2023;14(1):387.","journal-title":"Nat Commun"},{"issue":"1","key":"3709_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"issue":"7","key":"3709_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.trecan.2022.03.001","volume":"8","author":"PE Saw","year":"2022","unstructured":"Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends cancer. 2022;8(7):527\u201355.","journal-title":"Trends cancer"},{"key":"3709_CR22","doi-asserted-by":"crossref","unstructured":"Dezhi H, Naya M, Xinlei L, Yang G, Yishuo D, Bangdong L, Jing X, Xianlan Z, Xiaoqi W, Qiong L et al. Advances in single-cell RNA sequencing and its applications in cancer research. J Hematol Oncol 2023, 16(1).","DOI":"10.1186\/s13045-023-01494-6"},{"key":"3709_CR23","doi-asserted-by":"crossref","unstructured":"Wei G, Bolun Z, Zhenlin Y, Xiang L, Qilin H, Lei G, Xuemin X, Fengwei T, Yin L, Qi X et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma. EBioMedicine 2022, 84(0).","DOI":"10.1016\/j.ebiom.2022.104281"},{"issue":"1","key":"3709_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-023-01518-0","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li Y, Yu H, Ding Z, Chen L, Zeng X, He S, Liao Q, Zhao Y, Yuan Y. Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics. Signal Transduct Target Ther. 2023;8(1):298.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3709_CR25","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1038\/s41467-021-25539-x","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Peng L, Luo Y, Zhang S, Pu Y, Chen Y, Guo W, Yao J, Shao M, Fan W, et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat Commun. 2021;12(1):5291.","journal-title":"Nat Commun"},{"issue":"11","key":"3709_CR26","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/gutjnl-2013-305806","volume":"63","author":"J Li","year":"2014","unstructured":"Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. 2014;63(11):1700\u201310.","journal-title":"Gut"},{"issue":"12","key":"3709_CR27","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","volume":"27","author":"T van den Ende","year":"2021","unstructured":"van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman J, et al. Neoadjuvant chemoradiotherapy combined with Atezolizumab for resectable esophageal adenocarcinoma: A Single-arm phase II feasibility trial (PERFECT). Clin Cancer Res. 2021;27(12):3351\u20139.","journal-title":"Clin Cancer Res"},{"key":"3709_CR28","doi-asserted-by":"publisher","first-page":"101417","DOI":"10.1016\/j.smim.2020.101417","volume":"48","author":"R Mhaidly","year":"2020","unstructured":"Mhaidly R, Mechta-Grigoriou F. Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies. Semin Immunol. 2020;48:101417.","journal-title":"Semin Immunol"},{"issue":"5","key":"3709_CR29","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","volume":"73","author":"M Zhang","year":"2020","unstructured":"Zhang M, Yang H, Wan L, Wang Z, Wang H, Ge C, Liu Y, Hao Y, Zhang D, Shi G, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73(5):1118\u201330.","journal-title":"J Hepatol"},{"issue":"6","key":"3709_CR30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39(6):866\u2013e882811.","journal-title":"Cancer Cell"},{"issue":"4","key":"3709_CR31","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","volume":"72","author":"MA Martin-Serrano","year":"2023","unstructured":"Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut. 2023;72(4):736\u201348.","journal-title":"Gut"},{"issue":"1","key":"3709_CR32","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1038\/s41467-021-27599-5","volume":"12","author":"HQ Dinh","year":"2021","unstructured":"Dinh HQ, Pan F, Wang G, Huang QF, Olingy CE, Wu ZY, Wang SH, Xu X, Xu XE, He JZ, et al. Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nat Commun. 2021;12(1):7335.","journal-title":"Nat Commun"},{"issue":"1","key":"3709_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer Immunogenomic analyses reveal Genotype-Immunophenotype relationships and predictors of response to checkpoint Blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"key":"3709_CR34","doi-asserted-by":"crossref","unstructured":"Silva VSE, Abdallah EA, Flores BCT, Braun AC, Costa DJF, Ruano APC, Gasparini VA, Silva MLG, Mendes GG, Claro LCL et al. Molecular and dynamic evaluation of proteins related to resistance to neoadjuvant treatment with chemoradiotherapy in Circulating tumor cells of patients with locally advanced rectal Cancer. Cells 2021, 10(6).","DOI":"10.3390\/cells10061539"},{"key":"3709_CR35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fonc.2019.00974","volume":"9","author":"F Bettoni","year":"2019","unstructured":"Bettoni F, Masotti C, Corr\u00eaa BR, Donnard E, Dos Santos FF, S\u00e3o Juli\u00e3o GP, Vailati BB, Habr-Gama A, Galante PAF, Perez RO, et al. The effects of neoadjuvant chemoradiation in locally advanced rectal Cancer-The impact in intratumoral heterogeneity. Front Oncol. 2019;9:974.","journal-title":"Front Oncol"},{"issue":"5","key":"3709_CR36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ccell.2024.03.005","volume":"42","author":"N Niu","year":"2024","unstructured":"Niu N, Shen X, Wang Z, Chen Y, Weng Y, Yu F, Tang Y, Lu P, Liu M, Wang L, et al. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Cancer Cell. 2024;42(5):869\u2013e884869.","journal-title":"Cancer Cell"},{"key":"3709_CR37","doi-asserted-by":"crossref","unstructured":"Michael AH, Peter S, Balaji V, Megan MROM, Jasmine K, Scott NM, Laura KM, Roberto S, Sherene L. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer 2024, 24(8).","DOI":"10.1038\/s41568-024-00714-6"},{"issue":"9","key":"3709_CR38","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","volume":"27","author":"PM Galbo Jr","year":"2021","unstructured":"Galbo PM Jr., Zang X, Zheng D. Molecular features of Cancer-associated fibroblast subtypes and their implication on Cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res. 2021;27(9):2636\u201347.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3709_CR39","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13046-021-02108-0","volume":"40","author":"C Huang","year":"2021","unstructured":"Huang C, Ou R, Chen X, Zhang Y, Li J, Liang Y, Zhu X, Liu L, Li M, Lin D, et al. Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC. J Experimental Clin cancer Research: CR. 2021;40(1):304.","journal-title":"J Experimental Clin cancer Research: CR"},{"issue":"1","key":"3709_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/jcmm.14618","volume":"24","author":"H Lu","year":"2020","unstructured":"Lu H, Feng Y, Hu Y, Guo Y, Liu Y, Mao Q, Xue W. Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells. J Cell Mol Med. 2020;24(1):98\u2013113.","journal-title":"J Cell Mol Med"},{"key":"3709_CR41","doi-asserted-by":"publisher","first-page":"116630","DOI":"10.1016\/j.bone.2022.116630","volume":"167","author":"M Wu","year":"2023","unstructured":"Wu M, Kong D, Zhang Y. SPON2 promotes the bone metastasis of lung adenocarcinoma via activation of the NF-\u03baB signaling pathway. Bone. 2023;167:116630.","journal-title":"Bone"},{"issue":"7","key":"3709_CR42","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.ajpath.2019.04.007","volume":"189","author":"M Li","year":"2019","unstructured":"Li M, Wang L, Zhan Y, Zeng T, Zhang X, Guan XY, Li Y. Membrane metalloendopeptidase (MME) suppresses metastasis of esophageal squamous cell carcinoma (ESCC) by inhibiting FAK-RhoA signaling Axis. Am J Pathol. 2019;189(7):1462\u201372.","journal-title":"Am J Pathol"},{"issue":"9\u201310","key":"3709_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00335-010-9284-4","volume":"21","author":"RS Holmes","year":"2010","unstructured":"Holmes RS, Wright MW, Laulederkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M, Perkins EJ, et al. Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome. 2010;21(9\u201310):427\u201341.","journal-title":"Mamm Genome"},{"key":"3709_CR44","doi-asserted-by":"crossref","unstructured":"Li G, Li X, Mahmud I, Ysaguirre J, Fekry B, Wang S, Wei B, Eckel-Mahan KL, Lorenzi PL, Lehner R et al. Interfering with lipid metabolism through targeting CES1 sensitizes hepatocellular carcinoma for chemotherapy. JCI Insight 2023, 8(2).","DOI":"10.1172\/jci.insight.163624"},{"key":"3709_CR45","doi-asserted-by":"crossref","unstructured":"Hlav\u00e1\u010d V, V\u00e1clav\u00edkov\u00e1 R, Brynychov\u00e1 V, Ko\u017eevnikovov\u00e1 R, Kope\u010dkov\u00e1 K, Vr\u00e1na D, Gat\u011bk J, Sou\u010dek P. Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response. Int J Mol Sci 2020, 21(24).","DOI":"10.3390\/ijms21249556"},{"issue":"8","key":"3709_CR46","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00432-014-1831-z","volume":"141","author":"M Yamaguchi","year":"2015","unstructured":"Yamaguchi M. Involvement of Regucalcin as a suppressor protein in human carcinogenesis: insight into the gene therapy. J Cancer Res Clin Oncol. 2015;141(8):1333\u201341.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3709_CR47","doi-asserted-by":"publisher","first-page":"7553","DOI":"10.1038\/s41598-023-32217-z","volume":"13","author":"Y Liao","year":"2023","unstructured":"Liao Y, Cheng W, Mou R, Li X, Jia Y. RGN as a prognostic biomarker with immune infiltration and CeRNA in lung squamous cell carcinoma. Sci Rep. 2023;13(1):7553.","journal-title":"Sci Rep"},{"issue":"3","key":"3709_CR48","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783\u2013803.","journal-title":"Cancer Metastasis Rev"},{"key":"3709_CR49","doi-asserted-by":"crossref","unstructured":"Xin L, Yifan C, Kunpeng L, Yun G, Kaifeng J, Xudong H, Hanji F, Yuchao F, Mingsu S, Chao L et al. Tumor-infiltrating podoplanin(+) cells in gastric cancer: clinical outcomes and association with immune contexture. Oncoimmunology 2020, 9(1).","DOI":"10.1080\/2162402X.2020.1845038"},{"issue":"7710","key":"3709_CR50","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","volume":"558","author":"N Chihara","year":"2018","unstructured":"Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M, Nyman J, Marjanovic ND, Kowalczyk MS, Wang C, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018;558(7710):454\u20139.","journal-title":"Nature"},{"issue":"2","key":"3709_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","volume":"1871","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Ma X, Wei Y, Wei X. Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases. Biochim Et Biophys Acta Reviews cancer. 2019;1871(2):289\u2013312.","journal-title":"Biochim Et Biophys Acta Reviews cancer"},{"key":"3709_CR52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2020.03.013","volume":"479","author":"Y Takeyama","year":"2020","unstructured":"Takeyama Y, Kato M, Tamada S, Azuma Y, Shimizu Y, Iguchi T, Yamasaki T, Gi M, Wanibuchi H, Nakatani T. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer. Cancer Lett. 2020;479:89\u201399.","journal-title":"Cancer Lett"},{"issue":"5","key":"3709_CR53","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/cancers13051054","volume":"13","author":"A Chevign\u00e9","year":"2021","unstructured":"Chevign\u00e9 A, Janji B, Meyrath M, Reynders N, D\u2019Uonnolo G, Ucha\u0144ski T, Xiao M, Berchem G, Ollert M, Kwon Y-J, et al. CXCL10 is an agonist of the CC family chemokine scavenger receptor ACKR2\/D6. Cancers (Basel). 2021;13(5):1054.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"3709_CR54","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/bies.10136","volume":"24","author":"SE Jones","year":"2002","unstructured":"Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. BioEssays. 2002;24(9):811\u201320.","journal-title":"BioEssays"},{"issue":"15","key":"3709_CR55","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1101\/gad.14.15.1837","volume":"14","author":"P Polakis","year":"2000","unstructured":"Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837\u201351.","journal-title":"Genes Dev"},{"key":"3709_CR56","doi-asserted-by":"crossref","unstructured":"Cabrera-Mulero A, Crujeiras AB, Izquierdo AG, Torres E, Ayers D, Casanueva FF, Tinahones FJ, Morcillo S, Macias-Gonzalez M. Novel SFRP2 DNA methylation profile following neoadjuvant therapy in colorectal Cancer patients with different grades of BMI. J Clin Med 2019, 8(7).","DOI":"10.3390\/jcm8071041"},{"issue":"10","key":"3709_CR57","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","volume":"56","author":"MJ Pittet","year":"2023","unstructured":"Pittet MJ, Di Pilato M, Garris C, Mempel TR. Dendritic cells as shepherds of T cell immunity in cancer. Immunity. 2023;56(10):2218\u201330.","journal-title":"Immunity"},{"key":"3709_CR58","doi-asserted-by":"crossref","unstructured":"Ye Z, Kai WW. Tissue-Resident T cells in clinical response and immune-Related adverse events of immune checkpoint Blockade. Clin Cancer Res 2024, 30(24).","DOI":"10.1158\/1078-0432.CCR-23-3296"},{"key":"3709_CR59","unstructured":"Junru C, Xu H, Junjie Z, Xiaoxue Y, Linmao Z, Jingjing G, Jianhui C, Yongquan W, Xinan S, Haiying D et al. Memory\/Active T-Cell activation is associated with immunotherapeutic response in fumarate Hydratase-Deficient renal cell carcinoma. Clin Cancer Res 2024, 30(11)."},{"issue":"20","key":"3709_CR60","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159\u201367.","journal-title":"Blood"},{"key":"3709_CR61","first-page":"39","volume":"3","author":"NJ Llosa","year":"2014","unstructured":"Llosa NJ, Geis AL, Thiele Orberg E, Housseau F. Interleukin-17 and type 17 helper T cells in cancer management and research. ImmunoTargets Therapy. 2014;3:39\u201354.","journal-title":"ImmunoTargets Therapy"},{"issue":"15","key":"3709_CR62","doi-asserted-by":"publisher","first-page":"e2309591","DOI":"10.1002\/adma.202309591","volume":"36","author":"H Wang","year":"2024","unstructured":"Wang H, Chen Y, Wei R, Zhang J, Zhu J, Wang W, Wang Z, Wupur Z, Li Y, Meng H. Synergistic chemoimmunotherapy augmentation via sequential nanocomposite Hydrogel-Mediated reprogramming of Cancer-Associated fibroblasts in osteosarcoma. Adv Mater (Deerfield Beach Fla). 2024;36(15):e2309591.","journal-title":"Adv Mater (Deerfield Beach Fla)"},{"issue":"6","key":"3709_CR63","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","volume":"163","author":"J Datta","year":"2022","unstructured":"Datta J, Dai X, Bianchi A, De Castro Silva I, Mehra S, Garrido VT, Lamichhane P, Singh SP, Zhou Z, Dosch AR, et al. Combined MEK and STAT3 Inhibition uncovers stromal plasticity by enriching for Cancer-Associated fibroblasts with mesenchymal stem Cell-Like features to overcome immunotherapy resistance in pancreatic Cancer. Gastroenterology. 2022;163(6):1593\u2013612.","journal-title":"Gastroenterology"},{"key":"3709_CR64","doi-asserted-by":"crossref","unstructured":"Rui C, Ping W, Xin Z, Xiansheng L, Ruxia D, Xiaoyu W, Chang H, Jie L. Reticulocalbin3: A Ca(2+) homeostasis regulator that promotes esophageal squamous cell carcinoma progression and cisplatin resistance. Cancer Sci 2022, 113(10).","DOI":"10.1111\/cas.15487"},{"key":"3709_CR65","doi-asserted-by":"crossref","unstructured":"Hongtao L, Zhen Y, Qiuning Z, Lihua S, Shihong W, Ruifeng L, Zheng L, Yichao G, Chengcheng L, Xiaohu W. Carbon ion therapy inhibits esophageal squamous cell carcinoma metastasis by upregulating STAT3 through the JAK2\/STAT3 signaling pathway. Front Public Health 2020, 8(0).","DOI":"10.3389\/fpubh.2020.579705"},{"key":"3709_CR66","doi-asserted-by":"crossref","unstructured":"Manoj Kumar K, Arivusudar M, Suraj P, Ghantasala S, Sameer K, Harrys KCJ, Thottethodi Subrahmanya Keshava P, Riaz M, Veerendra KV, Vijaya KM, Stephen K. J M: Overexpression of Periostin and lumican in esophageal squamous cell carcinoma. Cancers (Basel) 2010, 2(1).","DOI":"10.3390\/cancers2010133"},{"key":"3709_CR67","doi-asserted-by":"crossref","unstructured":"I-Chen W, Deng-Chyang W, Chun-Chi H, Hung-Shun L, Yu-Kuei C, Hui-Jen T, Chieh-Yu L, Shah-Hwa C, Yi-Ping C, Ling-Hui L et al. Plasma decorin predicts the presence of esophageal squamous cell carcinoma. Int J Cancer 2010, 127(9).","DOI":"10.1002\/ijc.25239"},{"issue":"30","key":"3709_CR68","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1111\/1759-7714.15093","volume":"14","author":"J Du","year":"2023","unstructured":"Du J, Zhang S, Zhang X, Yang Z, Xue S, Xu G, Zheng B, Chen C. miR-1301-3p promotes invasion and migration and EMT progression in esophageal cancer by downregulating NBL1 expression. Thorac cancer. 2023;14(30):3032\u201341.","journal-title":"Thorac cancer"},{"key":"3709_CR69","doi-asserted-by":"crossref","unstructured":"Ruomu G, Zhengyun L, Ting G, Sheng X, Jun Y, Jie X. The expression and biological role of complement C1s in esophageal squamous cell carcinoma. Open Life Sci 2024, 19(1).","DOI":"10.1515\/biol-2022-0915"},{"issue":"Pt 2","key":"3709_CR70","doi-asserted-by":"publisher","first-page":"113482","DOI":"10.1016\/j.intimp.2024.113482","volume":"143","author":"H Tian","year":"2024","unstructured":"Tian H, Wang W, Liang S, Ding J, Hua D. From darkness to light: targeting CAFs as a new potential strategy for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113482.","journal-title":"Int Immunopharmacol"},{"issue":"36","key":"3709_CR71","doi-asserted-by":"publisher","first-page":"e2301257","DOI":"10.1002\/adma.202301257","volume":"35","author":"D Guo","year":"2023","unstructured":"Guo D, Ji X, Xie H, Ma J, Xu C, Zhou Y, Chen N, Wang H, Fan C, Song H. Targeted reprogramming of vitamin B(3) metabolism as a nanotherapeutic strategy towards chemoresistant cancers. Adv Mater (Deerfield Beach Fla). 2023;35(36):e2301257.","journal-title":"Adv Mater (Deerfield Beach Fla)"},{"key":"3709_CR72","doi-asserted-by":"crossref","unstructured":"Li Y, Cook KL, Yu W, Jin L, Bouker KB, Clarke R, Hilakivi-Clarke L. Inhibition of Antiestrogen-Promoted Pro-Survival autophagy and Tamoxifen resistance in breast Cancer through vitamin D receptor. Nutrients 2021, 13(5).","DOI":"10.3390\/nu13051715"},{"key":"3709_CR73","doi-asserted-by":"crossref","unstructured":"Lee YE, Go GY, Koh EY, Yoon HN, Seo M, Hong SM, Jeong JH, Kim JC, Cho D, Kim TS et al. Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6. J Immunother Cancer 2023, 11(2).","DOI":"10.1136\/jitc-2022-006130"},{"key":"3709_CR74","doi-asserted-by":"crossref","unstructured":"Hu J, Lazar AJ, Ingram D, Wang WL, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K et al. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer 2024, 12(1).","DOI":"10.1136\/jitc-2023-006991"},{"issue":"3","key":"3709_CR75","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/2326-6066.CIR-14-0002","volume":"2","author":"DT Fearon","year":"2014","unstructured":"Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res. 2014;2(3):187\u201393.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"3709_CR76","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1080\/15548627.2023.2300913","volume":"20","author":"X Zhang","year":"2024","unstructured":"Zhang X, Lao M, Yang H, Sun K, Dong Y, He L, Jiang X, Wu H, Jiang Y, Li M, et al. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Autophagy. 2024;20(6):1314\u201334.","journal-title":"Autophagy"},{"issue":"9","key":"3709_CR77","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","volume":"80","author":"K Ford","year":"2020","unstructured":"Ford K, Hanley CJ, Mellone M, Szyndralewiez C, Heitz F, Wiesel P, Wood O, Machado M, Lopez MA, Ganesan AP, et al. NOX4 Inhibition potentiates immunotherapy by overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell exclusion from tumors. Cancer Res. 2020;80(9):1846\u201360.","journal-title":"Cancer Res"},{"key":"3709_CR78","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, et al. Angiotensin Inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.","journal-title":"Nat Commun"},{"issue":"12","key":"3709_CR79","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","volume":"22","author":"SR Hingorani","year":"2016","unstructured":"Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, et al. Phase Ib study of pegylated Recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic Cancer. Clin Cancer Res. 2016;22(12):2848\u201354.","journal-title":"Clin Cancer Res"},{"key":"3709_CR80","doi-asserted-by":"publisher","first-page":"758400","DOI":"10.3389\/fcell.2021.758400","volume":"9","author":"SK Riaz","year":"2021","unstructured":"Riaz SK, Khan W, Wang F, Khaliq T, Malik A, Razia ET, Khan JS, Haque S, Hashem AM, Alkhayyat SS, et al. Targeted Inhibition of fibroblast growth factor receptor 1-GLI through AZD4547 and GANT61 modulates breast Cancer progression. Front Cell Dev Biology. 2021;9:758400.","journal-title":"Front Cell Dev Biology"},{"issue":"2","key":"3709_CR81","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s12072-023-10603-z","volume":"18","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Imamura Y, Masuda A, Nakamura T, Koga H, Hoshida Y, Kawaguchi T. Fibroblast growth factor Inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma. Hepatol Int. 2024;18(2):610\u201322.","journal-title":"Hepatol Int"},{"issue":"9","key":"3709_CR82","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1200\/JCO.20.02755","volume":"39","author":"MA Shah","year":"2021","unstructured":"Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, et al. Phase III study to evaluate efficacy and safety of andecaliximab with mFOLFOX6 as First-Line treatment in patients with advanced gastric or GEJ adenocarcinoma (GAMMA-1). J Clin Oncol. 2021;39(9):990\u20131000.","journal-title":"J Clin Oncol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03709-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T11:23:52Z","timestamp":1740828232000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03709-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3709"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03709-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human studies were approved by the Jinling hospital ethics committee (Medical School of Nanjing University), based on the Declaration of Helsinki (2024DZGJJ-406). Written consent was obtained from each patient before surgery.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}